Sirolimus Eye Drops for Meibomian Gland Obstruction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is no effective treatment method for meibomian gland dysfunction (MGD), and existing diagnostic criteria are unclear, leading to challenges in managing the condition, which can cause chronic ocular discomfort and dry eye.
Innovation Solution
A compound represented by a specific formula, or its pharmaceutically acceptable salt, is used as a prophylactic and/or therapeutic agent to reduce obstructions at the meibomian gland orifices and treat MGD, preferably in the form of eye drops or ointments for instillation or application to the eyelid skin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If meibomian gland obstruction is treated with conventional methods, then general ocular comfort may be maintained, but the obstruction itself persists and continues to cause MGD symptoms
Solution Approach 1:
The patent uses a specific compound (formula 1) as an intermediary substance that mediates between the obstructed meibomian gland and the therapeutic effect. The compound acts as a mediator that specifically targets and resolves the obstruction mechanism without affecting other ocular structures, thereby improving treatment reliability while eliminating the harmful obstruction factor.
Solution Approach 2:
The patent changes the chemical parameter of the treatment by introducing a compound with specific functional groups (hydroxyl, methoxy, carboxyl, etc.) that can interact with the obstruction material. This parameter change in chemical composition allows the treatment to specifically address the obstruction while maintaining overall ocular homeostasis.
2Measurement precision
If diagnostic criteria for MGD are established, then MGD can be defined as an independent disease, but clear diagnostic standards remain lacking
Solution Approach 1:
The patent replaces complex clinical diagnostic procedures with a simpler chemical detection method. By using a compound that specifically interacts with MGD-related substances, the diagnosis can be made through chemical analysis rather than complex clinical evaluation, thereby improving measurement precision without increasing device or procedural complexity.
3Quantity of substance
If meibomian gland secretion is increased to compensate for obstruction, then lipid delivery may improve, but gland dysfunction and ocular discomfort persist
Solution Approach 1:
The patent extracts or removes the obstruction factor from the meibomian gland system using the compound of formula (1). By taking out the obstructing substance or mechanism, the gland can function normally without needing to compensate through increased secretion, thereby improving lipid delivery while eliminating gland dysfunction and associated ocular discomfort.
Data Source
AI summary
A method for suppressing obstruction of meibomian gland in a mammalian subject, the method comprising administering to the mammalian subject an eye drop comprising 0.01 to 0.5% (w/v) of sirolimus or a pharmaceutically acceptable salt thereof as a sole active ingredient, wherein the eye drop is administered to an eye of the mammalian subject 1 to 2 times per day.